We have located links that may give you full text access.
Optic neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term survey.
Neurology 1999 August 12
OBJECTIVE: To determine the predictive value on survival of optic neuritis (ON) as onset manifestation of MS.
METHODS: We used data obtained from the Danish Multiple Sclerosis Registry, which includes virtually all patients diagnosed with MS in Denmark. From 1949 to 1990, 7,548 unselected patients fulfilling standardized diagnostic criteria of MS were registered.
RESULTS: The onset manifestation of MS was known in 6,923 patients, and was ON in 1,282 patients (19%). The mean age at onset was 31.1 years for these patients compared with 34.8 years for patients with another or unknown onset manifestation of MS (non-ON) (p < 0.001). The mean delay from the first known manifestation of MS to the final diagnosis of MS was 6.1 years (ON) and 4.2 years (non-ON). The median survival time from onset of ON was 30 years in men (compared with 41 years in the matched general male population) and 40 years in women (versus 47 years). The excess death rate increased with age at onset of MS in people of each sex. Excess death rate for women differed significantly between patients with ON as onset manifestation and patients with another or unknown onset manifestation of MS (8.3 versus 13.0). In patients with ON as onset manifestation of MS, the excess death rate was significantly higher in men (14.0) than in women (8.3).
CONCLUSION: ON as onset manifestation of MS indicates a more favorable prognosis of survival of MS judged by excess death rate only in women.
METHODS: We used data obtained from the Danish Multiple Sclerosis Registry, which includes virtually all patients diagnosed with MS in Denmark. From 1949 to 1990, 7,548 unselected patients fulfilling standardized diagnostic criteria of MS were registered.
RESULTS: The onset manifestation of MS was known in 6,923 patients, and was ON in 1,282 patients (19%). The mean age at onset was 31.1 years for these patients compared with 34.8 years for patients with another or unknown onset manifestation of MS (non-ON) (p < 0.001). The mean delay from the first known manifestation of MS to the final diagnosis of MS was 6.1 years (ON) and 4.2 years (non-ON). The median survival time from onset of ON was 30 years in men (compared with 41 years in the matched general male population) and 40 years in women (versus 47 years). The excess death rate increased with age at onset of MS in people of each sex. Excess death rate for women differed significantly between patients with ON as onset manifestation and patients with another or unknown onset manifestation of MS (8.3 versus 13.0). In patients with ON as onset manifestation of MS, the excess death rate was significantly higher in men (14.0) than in women (8.3).
CONCLUSION: ON as onset manifestation of MS indicates a more favorable prognosis of survival of MS judged by excess death rate only in women.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app